Lp(a) Lab Results: Normal Reference Range vs. Functional Optimal Levels

What Is Lp(a) and Why Does It Matter?

Lipoprotein(a), abbreviated Lp(a), is a lipoprotein particle made up of an LDL-like core with apolipoprotein(a) covalently bonded to apolipoprotein B-100. It circulates in the blood and contributes to atherosclerosis through three overlapping mechanisms: cholesterol deposition in artery walls, pro-inflammatory signaling, and inhibition of fibrinolysis (the body's clot-dissolving pathway) [1].

The European Atherosclerosis Society (EAS) identified Lp(a) as a causal, independent risk factor for cardiovascular disease (CVD) in its 2010 consensus statement, a position reaffirmed and strengthened in the 2022 update [2]. Unlike LDL cholesterol, which responds predictably to statins and dietary changes, Lp(a) levels are overwhelmingly set by genetics. The LPA gene on chromosome 6 accounts for more than 90% of the variance in circulating Lp(a) concentrations [3]. This means that if your Lp(a) is high, it was likely high at birth, it will stay high without targeted intervention, and your first-degree relatives may carry the same risk.

Roughly one in five people worldwide has Lp(a) above 50 mg/dL [2]. That is not a rare finding. It is a prevalent, undertested, and underrecognized contributor to heart attack, stroke, and calcific aortic valve stenosis.

The Standard Lab Reference Range

Most commercial labs in the United States report Lp(a) with a reference range that flags values above 30 mg/dL (or 75 nmol/L) as elevated. This threshold traces back to population-distribution data: approximately 80% of people fall below 30 mg/dL, so the cutoff marks the statistical upper end of "common" [4].

The 2018 AHA/ACC Cholesterol Guideline uses Lp(a) ≥50 mg/dL (≥125 nmol/L) as a "risk-enhancing factor" that can tip borderline-risk patients toward statin therapy [5]. The EAS 2022 consensus uses the same 50 mg/dL threshold for defining meaningfully elevated cardiovascular risk [2].

Here is the problem with relying on these cutoffs alone. A patient with Lp(a) of 35 mg/dL gets a lab report that reads "within normal limits" at many reference laboratories. That patient still carries a measurably higher cardiovascular risk than someone at 10 mg/dL. The Copenhagen General Population Study (N=69,764) demonstrated a continuous, dose-dependent relationship between Lp(a) concentration and myocardial infarction risk, with no clear "safe" floor [6]. Risk does not switch on at 30 or 50 mg/dL. It accumulates along a gradient.

Functional Optimal: Where Preventive Cardiologists Draw the Line

Functional and preventive cardiology practitioners set a tighter target: Lp(a) below 14 mg/dL (35 nmol/L). This number comes from the risk-gradient data showing that cardiovascular event rates flatten out only at very low Lp(a) concentrations [6].

Dr. Benoit Arsenault, a lipid researcher at the Quebec Heart and Lung Institute, stated in a 2020 review: "The relationship between Lp(a) and cardiovascular risk is continuous and graded, and there is no concentration below which risk is completely absent" [7]. That observation is the core reason preventive cardiologists prefer a lower target than conventional lab references suggest.

The practical framework for interpreting your Lp(a) result breaks into three tiers:

Tier 1: Optimal (below 14 mg/dL / 35 nmol/L). Minimal Lp(a)-attributable cardiovascular risk. No Lp(a)-specific intervention needed. Standard lipid management applies.

Tier 2: Borderline (14 to 50 mg/dL / 35 to 125 nmol/L). Modest independent risk. Aggressive management of all other modifiable risk factors (LDL-C, blood pressure, glucose, smoking, body composition) becomes more important because Lp(a) itself is difficult to lower.

Tier 3: High (above 50 mg/dL / 125 nmol/L). Significant independent risk, roughly equivalent to the lifetime risk conferred by heterozygous familial hypercholesterolemia [2]. Warrants discussion of PCSK9 inhibitors for concurrent LDL reduction, cascade screening of family members, and potential enrollment in Lp(a)-lowering clinical trials.

Units Matter: mg/dL vs. nmol/L

This is a frequent source of confusion, and it has clinical consequences. Lp(a) can be reported in mg/dL (mass-based) or nmol/L (molar-based). The two units are not interchangeable with a simple conversion factor because Lp(a) particle size varies between individuals due to differences in apolipoprotein(a) isoform size [8].

The EAS and the National Heart, Lung, and Blood Institute (NHLBI) both recommend reporting Lp(a) in nmol/L using isoform-insensitive assays for greatest accuracy [3]. Many U.S. labs still report in mg/dL. When a lab uses mg/dL, multiplying by 2.5 gives a rough nmol/L estimate, but this approximation can be off by 30% or more in patients with very small or very large apo(a) isoforms [8].

If your lab reports Lp(a) in mg/dL and the value sits near a decision threshold (for example, 28 mg/dL), requesting a repeat test using an nmol/L-based immunoassay may provide a more reliable classification.

Why Is Lp(a) So Hard to Change?

Lp(a) concentrations resist the interventions that reliably lower LDL cholesterol. Statins do not reduce Lp(a); several analyses show they may increase it by 10 to 20% [9]. Diet and exercise produce negligible changes. Even weight loss, which improves nearly every other metabolic marker, has minimal effect on Lp(a) [3].

The agents with documented Lp(a)-lowering effects are limited:

Niacin reduces Lp(a) by roughly 20 to 30% at doses of 1 to 3 g/day [10]. The AIM-HIGH trial (N=3,414), however, showed no reduction in cardiovascular events when niacin was added to statin therapy, dampening enthusiasm for this approach [11].

PCSK9 inhibitors (evolocumab, alirocumab) lower Lp(a) by approximately 20 to 30% as a secondary effect [12]. In a post-hoc analysis of the FOURIER trial (N=27,564), evolocumab reduced cardiovascular events more in patients with higher baseline Lp(a), and the Lp(a) reduction appeared to contribute independently of LDL-C lowering [12].

Pelacarsen (an antisense oligonucleotide targeting hepatic LPA mRNA) reduced Lp(a) by up to 80% in the phase II trial (N=286) [13]. The phase III Lp(a)HORIZON trial (NCT04023552, target N=8,323) is evaluating whether this translates to fewer cardiovascular events, with results expected in 2026 or 2027 [14].

Olpasimra (previously SLN360), another antisense agent, and muvalaplin, an oral small molecule that blocks Lp(a) assembly, are both in active clinical development [15]. No Lp(a)-specific therapy has received FDA approval as of May 2026.

How Lp(a) Interacts with Other Risk Factors

Lp(a) does not operate in a vacuum. Its risk compounds when other cardiovascular risk factors are present. The 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias state: "Very high Lp(a) levels, combined with high LDL-C, confer a risk comparable to that observed in heterozygous familial hypercholesterolaemia" [16].

A patient with Lp(a) of 60 mg/dL and LDL-C of 70 mg/dL has a different risk profile than one with the same Lp(a) and LDL-C of 160 mg/dL. The second patient faces a multiplicative burden. This is why aggressive LDL-C reduction becomes the primary actionable strategy in patients with elevated Lp(a): you cannot easily lower the Lp(a), so you compensate by driving LDL-C well below standard targets.

The 2018 AHA/ACC guideline explicitly includes Lp(a) ≥50 mg/dL among the risk-enhancing factors that justify initiating or intensifying statin therapy in intermediate-risk adults [5]. Some preventive cardiologists go further, targeting LDL-C below 70 mg/dL (and even below 55 mg/dL, per ESC/EAS recommendations) in patients with high Lp(a) and additional risk factors [16].

Coronary artery calcium (CAC) scoring provides useful risk refinement. A patient with elevated Lp(a) but a CAC score of zero may warrant monitoring rather than pharmacotherapy. A patient with the same Lp(a) and a CAC score above 100 likely benefits from aggressive intervention [5].

Who Should Get Tested?

The EAS recommends that every adult be tested for Lp(a) at least once in their lifetime to identify those at high genetic risk [2]. The 2018 AHA/ACC guideline supports Lp(a) measurement as a risk-enhancing factor assessment in patients at borderline or intermediate 10-year ASCVD risk [5].

Specific populations with a stronger testing indication include:

• Adults with premature ASCVD (men before age 55, women before age 65)
• Anyone with a family history of premature cardiovascular events
• Patients with familial hypercholesterolemia or LDL-C that remains elevated despite treatment
• Individuals with recurrent cardiovascular events on optimized statin therapy
• First-degree relatives of someone with Lp(a) above 50 mg/dL
• Patients with calcific aortic valve stenosis of unclear etiology

Because Lp(a) is genetically fixed, a single measurement is generally sufficient. Retesting is only warranted to verify the initial result, to switch from a mass-based to a molar-based assay, or after initiating a therapy with known Lp(a)-lowering activity (such as a PCSK9 inhibitor) [2].

The "Normal" Label Can Create False Reassurance

A 42-year-old man receives a lab result showing Lp(a) of 38 mg/dL. His report says "within normal limits." He files it away. His father had a heart attack at 58. His LDL-C is 145 mg/dL. His 10-year ASCVD risk score sits at 6.8%, below the statin initiation threshold.

Under standard practice, this patient might not receive a statin for another decade. But his Lp(a) of 38 mg/dL, combined with a family history of premature CVD, places him in a higher-risk category than his pooled cohort equation score suggests. The 2018 AHA/ACC guideline identifies precisely this scenario as one where Lp(a) measurement can reclassify risk upward and justify earlier statin therapy [5].

The word "normal" on a lab report carries implicit reassurance. For Lp(a), that reassurance may be premature. A result that falls between 14 and 50 mg/dL is not a reason for alarm, but it is a reason to optimize every other modifiable risk factor with greater urgency.

What You Can Do if Your Lp(a) Is Elevated

No approved drug specifically targets Lp(a) yet. That does not mean nothing can be done. The clinical strategy focuses on total atherosclerotic burden reduction.

Lower LDL-C aggressively. For patients with Lp(a) above 50 mg/dL, many preventive cardiologists target LDL-C below 70 mg/dL using statins, ezetimibe, and if needed, PCSK9 inhibitors [16]. PCSK9 inhibitors carry the additional benefit of modestly lowering Lp(a) itself [12].

Control blood pressure. Hypertension compounds the endothelial damage that Lp(a) promotes. Keeping systolic blood pressure below 130 mmHg aligns with ACC/AHA targets for patients at elevated cardiovascular risk [17].

Optimize metabolic health. Insulin resistance and type 2 diabetes amplify cardiovascular risk independently. Maintaining hemoglobin A1c below 7% (or below 6.5% for prevention-focused patients) reduces the total burden on arterial walls.

Do not smoke. Smoking accelerates every mechanism through which Lp(a) damages blood vessels.

Consider aspirin carefully. Some clinicians prescribe low-dose aspirin for high-Lp(a) patients given the prothrombotic properties of Lp(a), but the net benefit depends on individual bleeding risk. The USPSTF recommends shared decision-making for aspirin in adults 40 to 59 with 10-year ASCVD risk of 10% or greater [18].

Ask about clinical trials. Patients with Lp(a) above 70 mg/dL (175 nmol/L) may qualify for the Lp(a)HORIZON trial or other active studies evaluating pelacarsen, olpasimra, or muvalaplin [14]. ClinicalTrials.gov lists active recruitment sites.

The 2022 EAS consensus recommends that clinicians treat elevated Lp(a) as an "LDL-C-lowering indication amplifier," meaning the higher the Lp(a), the more aggressively other lipid targets should be pursued [2].